GenVec (GNVC) Says Novartis (NVS) Remains Committed to CGF166 Amid Internal Changes
- Stocks face worst month since September, yen swings after BoJ
- Microsoft fiscal Q3 results top estimates as AI revolution spurs cloud growth
- Alphabet stock surges 11% to record high on Q1 earnings beat, first-ever dividend
- Intel slides in afterhours trading as Q1 revenue misses, Q2 outlook falls short
- Oil prices on track to snap two-week losing streak
- Rubrik (RBRK) Prices Upsized 23.5M Share IPO at $32/sh
- Union Pacific beats profit estimates on stronger pricing, resumes share buyback
- IBM tumbles on soft Q1 revenue; announces HashiCorp $6.4bn acquisition
- Hertz Global (HTZ) misses earnings expectations as fleet costs weigh
- Teladoc (TDOC) Misses Q1 EPS by 3c, offers outlook
- After-hours movers: Alphabet, Microsoft, Snap, Intel, and more
- Midday movers: Meta, IBM, Caterpillar fall; Chipotle rises
- After-hours movers: Meta, Ford, IBM, ServiceNow and more
- Midday movers: Tesla, Boeing rise; Uber, Old Dominion Freight fall
- After-hours movers: Tesla, Texas Instruments, Seagate, Visa and more
Novartis (NVS) Announces Publication of Positive Sandoz AirFluSal Forspiro Data vs Reference Product
August 31, 2016 2:40 PM EDTNew data just published in a leading medical journal shows for the first time that the rate of treatment persistence for patients using the innovative Sandoz AirFluSal Forspiro respiratory inhaler is more than twice as high as for the reference product.
Persistence to treatment is defined as the duration of time from initiation to discontinuation of treatment [1]. Dr. Bruce Bender, the lead author on the paper, said: "COPD and asthma are long term diseases requiring long-term, persistent adherence to therapy. While adherence has been widely studied to date, a growing awareness of the large number of patients who... More
Why Teva Pharma (TEVA) Should Settle With Novartis - Leerink
August 31, 2016 7:18 AM EDTLeerink Partners analyst, Jason Gerberry, reiterated his Outperform rating on Teva Pharma (NYSE: TEVA) and cut the price target to $61 from $66. After losing an IPR decision on two Copaxone 40mg anchor patents, the analyst believes TEVAs share price implies a generic entrant... More